Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emily R Hajjar

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Clinics in Geriatric Medicine|April 17, 2012
Polypharmacy, adverse drug reactions, and geriatric syndromesBhavik M Shah, Emily R Hajjar
Journal of the American Medical Directors Association|June 5, 2018
Isn't It Time We Stop Counting the Number of Drugs to Define Polypharmacy in This New Era of Deprescribing and What Related Outcomes Should Be Measured?Joseph T Hanlon, Emily R Hajjar
Primary Care|May 22, 2012
Chronic disease management: the changing landscape of primary careBrooke Salzman, Lauren Collins, Emily R Hajjar
JCO Oncology Practice|June 24, 2022
Cannabis Use in Patients With Cancer: A Clinical ReviewBrooke Worster, Emily R Hajjar, Nathan Handley
Expert Opinion on Drug Safety|October 1, 2013
Clinical consequences of polypharmacy in elderlyRobert L Maher, Joseph Hanlon, Emily R Hajjar
Current Oncology Reports|September 25, 2017
Polypharmacy in the Geriatric Oncology PopulationLauren R Hersh, Kathryn Beldowski, Emily R Hajjar
The American Journal of Geriatric Pharmacotherapy|January 9, 2008
Polypharmacy in elderly patientsEmily R Hajjar, Angela C Cafiero, Joseph T Hanlon
The Journal of Family Practice|July 13, 2017
Deprescribing: A simple method for reducing polypharmacyKathryn McGrath, Emily R Hajjar, Chandrika Kumar, et al.
The American Journal of Geriatric Pharmacotherapy|November 24, 2004
Update on drug-related problems in the elderlyJoseph T Hanlon, Catherine I Lindblad, Emily R Hajjar, et al.
Complementary Therapies in Clinical Practice|June 6, 2022
Characterizing anxiety, pain, sleep, and quality of life among patients in a state Medical Marijuana ProgramRebecca L Ashare, Erin Kelly, Emily R Hajjar, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Clinics in Geriatric Medicine|April 17, 2012
Polypharmacy, adverse drug reactions, and geriatric syndromesBhavik M Shah, Emily R Hajjar
Journal of the American Medical Directors Association|June 5, 2018
Isn't It Time We Stop Counting the Number of Drugs to Define Polypharmacy in This New Era of Deprescribing and What Related Outcomes Should Be Measured?Joseph T Hanlon, Emily R Hajjar
Primary Care|May 22, 2012
Chronic disease management: the changing landscape of primary careBrooke Salzman, Lauren Collins, Emily R Hajjar
JCO Oncology Practice|June 24, 2022
Cannabis Use in Patients With Cancer: A Clinical ReviewBrooke Worster, Emily R Hajjar, Nathan Handley
Expert Opinion on Drug Safety|October 1, 2013
Clinical consequences of polypharmacy in elderlyRobert L Maher, Joseph Hanlon, Emily R Hajjar
Current Oncology Reports|September 25, 2017
Polypharmacy in the Geriatric Oncology PopulationLauren R Hersh, Kathryn Beldowski, Emily R Hajjar
The American Journal of Geriatric Pharmacotherapy|January 9, 2008
Polypharmacy in elderly patientsEmily R Hajjar, Angela C Cafiero, Joseph T Hanlon
The Journal of Family Practice|July 13, 2017
Deprescribing: A simple method for reducing polypharmacyKathryn McGrath, Emily R Hajjar, Chandrika Kumar, et al.
The American Journal of Geriatric Pharmacotherapy|November 24, 2004
Update on drug-related problems in the elderlyJoseph T Hanlon, Catherine I Lindblad, Emily R Hajjar, et al.
Complementary Therapies in Clinical Practice|June 6, 2022
Characterizing anxiety, pain, sleep, and quality of life among patients in a state Medical Marijuana ProgramRebecca L Ashare, Erin Kelly, Emily R Hajjar, et al.
Pageof 2